BridgeBio Pharma, Inc.

BBIO

US10806X1028

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:39:24 2024-05-21 am EDT			5-day change	1st Jan Change
29.54 ^USD	+0.05%		+2.14%	-26.75%

May. 16	Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
May. 06	Certain Restricted Stock Unit Awards of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI

Bridgebio Pharma Announces the Resignation of Brian Stolz as Chief Operating Officer of the Company

October 23, 2020 at 04:33 pm EDT

BridgeBio Pharma, Inc. announced that on October 21, 2020, it was agreed that Brian Stolz, Chief Operating Officer of the company would be ending his employment with the Company effective as of the close of business on October 22, 2020. The Company is currently evaluating its need for a chief operating officer to replace Mr. Stolz.

Latest news about BridgeBio Pharma, Inc.

Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	May. 15
Certain Restricted Stock Unit Awards of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	May. 05	CI
Certain Options of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	May. 05	CI
Certain Common Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	May. 05	CI
BridgeBio Pharma Shares Decline After Q1 Financial Results	May. 02	MT
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M	May. 02	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
BridgeBio Pharma, Inc. announced that it has received $200 million in funding from a group of investors	May. 01	CI
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	Apr. 07	CI
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	Mar. 20	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	Mar. 19	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	Mar. 11	MT
BridgeBio Pharma Prices $250 Million Stock Offering	Mar. 06	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05	MT
BridgeBio Pharma Commences $250 Million Share Offering	Mar. 04	MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	Mar. 04	MT
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	Mar. 04	MT
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	Mar. 04	RE
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	Mar. 04	CI
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating	Feb. 23	MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating	Feb. 23	MT
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	Feb. 22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q4 Revenue $1.7M	Feb. 22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI

Chart BridgeBio Pharma, Inc.

Duration

Period

More charts

Company Profile

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Sector

Pharmaceuticals

Calendar

2024-06-21 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BridgeBio Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.52 USD

Average target price

50.23 USD

Spread / Average Target

+70.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BRIDGEBIO PHARMA, INC.	-26.75%	5.52B
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.34B
BIOGEN INC.	-11.88%	33.72B
UCB	+61.22%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-20.29%	14.63B
INCYTE CORPORATION	-8.78%	12.84B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	8.92B

Biopharmaceuticals

BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Pharmaceuticals

Bridgebio Pharma Announces the Resignation of Brian Stolz as Chief Operating Officer of the Company

EPS Revisions